{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053195","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.295397+00:00","generated_at":"2026-06-02T22:07:04.396316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Stoke Therapeutics Q1 net loss $26.4M; STK-001 data supports disease modification","bullets":["Net loss $26.4M ($0.57/share) vs $22.5M ($0.53) YoY; cash $178.6M at March 31, plus $120.3M net from April follow-on offering.","STK-001 data from 81 patients showed durable seizure reductions and cognitive/behavior improvements; plans to discuss registrational study with regulators, update H2 2024.","Revenue from Acadia collaboration $4.2M (down from $5.2M); R&D expenses rose to $22.4M from $19.6M.","Appointed Jason Hoitt as CCO and Tommy Leggett as CFO.","Plans to initiate Phase 1 OSPREY trial for STK-002 in ADOA in 2024; FALCON natural history data presented at ARVO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053195","json":"https://secwatch.observer/filing/0000950170-24-053195.json","markdown":"https://secwatch.observer/filing/0000950170-24-053195.md","text":"https://secwatch.observer/filing/0000950170-24-053195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000095017024053195/0000950170-24-053195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000095017024053195/stok-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:07:04.396316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07679e4a9e06b5840d380366389175906fa7c8f7","claim":"Stoke Therapeutics, Inc. reported the three months ended March 31, 2024 results: revenue $4.2 million, net income $26.4 million, EPS $0.57 per share.","evidence_excerpt":"Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the three months ended March 31, 2024 was $4.2 million, compared to $5.2 million, for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000095017024053195/0000950170-24-053195-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$4.2 million"},{"label":"Net income","value":"$26.4 million"},{"label":"EPS","value":"$0.57 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}